Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
07:00am, Thursday, 20'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralese Technologies reports complete response in preclinical lung cancer model
08:25am, Wednesday, 19'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF). (TSXV OTCQB), a clinical-stage pharmaceutical company specializing in light and radiation-activated therapies, has announced that its lead drug for
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
07:00am, Wednesday, 19'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase Technologies reports lead drug Rutherrin enhances immunotherapy
10:32am, Tuesday, 18'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new preclinical research has shown its lead drug formulation Rutherrin has demonstrated the ability to increase the efficiency of imm
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
07:00am, Tuesday, 18'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase reports preclinical research shows Rutherrin enhances chemotherapy efficacy
11:55am, Wednesday, 12'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that preclinical research results for its lead drug formulation, Rutherrin, has demonstrated its effectiveness in enhancing chemotherapy e
Rutherrin(R) Increases Efficacy of Chemotherapy
07:00am, Wednesday, 12'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase Technologies hails new combination treatment for NMI bladder cancer in pre-clinical tests
09:51am, Monday, 10'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) said that a combination of its lead compound with a widely used treatment to make a much more effective therapy for non-muscle invasive bladder
Ruvidar(TM) Enhances Efficacy of Cancer Drug
07:00am, Monday, 10'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase Technologies Inc. (TLTFF) Q1 2024 Earnings Call Transcript
02:34pm, Thursday, 06'th Jun 2024
Theralase Technologies Inc. (OTCQX:TLTFF) Q1 2024 Results Conference Call June 6, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Offic
Theralase eyes Phase 1a trial for lung cancer therapy after preclinical success
08:44am, Thursday, 06'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead compound Rudivar combined with transferrin to form the compound Rutherrin has been shown to be effective in the destruction
Theralase(R) Successfully Destroys Lung Cancer
07:00am, Thursday, 06'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the res
Theralase Technology unveils new research showing Rudivar's effectiveness against multiple viruses
09:55am, Tuesday, 04'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new research has shown that its lead asset Rudivar has proven effective in the inactivation of various viruses. The company, which
Theralase(R) Technology Effective in Virus Inactivation
07:00am, Tuesday, 04'th Jun 2024
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase narrows Q1 loss as it advances bladder cancer trial
09:31am, Thursday, 30'th May 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) continued to advance its lead asset, bladder cancer treatment Rudivar, in the first quarter of 2024. The firm is evaluating Rudivar activated by
